Sign in
CompletedPhase 2/3

Fluids in Septic Shock (FISSH)

Key facts

Who runs it
McMaster University
Where
Canada and Saudi Arabia30 sites in 2 countriesChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2/3
People taking part
1,113 people enrolled
Started
9 Sept 2018
Ended
10 Feb 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • higher chloride crystalloid
  • lower chloride crystalloid
Record updated
27 February 2026

Who can take part

Age
16 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • patients 16 years or greater who meet all of the following:
  • require fluid resuscitation for refractory hypotension (systolic blood pressure <90 mmHg or mean arterial blood pressure<65 mmHg after 1 Litre bolus over 1 hour or less or organ hypo-perfusion (serum lactate >4 mmol/L)
  • have a clinical suspicion of infection
  • are within 6 hours of hospital admission or critical care response team consultation
  • are anticipated to require ICU admission

Who cannot take part

  • have previously enrolled in FISSH, or a confounding trial (e.g. a trial examining the effect of other intravenous fluids in septic shock patients)
  • pre-established end stage renal disease (ESRD) or are receiving hemodialysis (intermittent or continuous) at time of enrolment, or
  • intracranial bleed or intracranial hypertension during the index hospital admission
  • bleeding/hemorrhage as likely cause of hypotension
  • 10% of body surface area acute burn injury
  • a lack of commitment to life support
  • been transferred from another hospital or facility >6 hours since presentation to first hospital
  • been admitted to ICU directly from the operating room or post anaesthetic care unit

This trial has no sites in United States.

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

Despite evidence of the physiologic benefits and possible lower mortality associated with low chloride solutions, normal saline remains the most wildly used fluid in the world. Given uncertainty about the impact of lower chloride versus higher chloride solutions on mortality, it is unlikely that clinical practice will change without new and direct randomized controlled trial (RCT) evidence. Editorials published in leading critical care journals have called for RCT's to address this important clinical question. This trial will directly compare low chloride versus normal chloride for resuscitation in septic shock on patient-important outcomes such as mortality and AKI.

The 2 groups in the trial

  • higher chloride solutionsExisting treatment, for comparison

    higher chloride crystalloid (Normal saline - chloride concentration 154 mmol/L)

    Treatment: higher chloride crystalloid

  • lower chloride solutionsExisting treatment, for comparison

    lower chloride crystalloid (Ringer's lactate - chloride concentration 110 mmol/L)

    Treatment: lower chloride crystalloid

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Fluids in Septic Shock (FISSH): a Randomized Controlled Trial
Record updated
27 February 2026